Current strategies of antiarrhythmic drug therapy for paroxysmal atrial fibrillation

Sciencedirect.com: June 7, 2012.

Atrial fibrillation is now recognized as a significant medical and social problem. Atrial fibrillation not only causes cardiovascular complications, including thromboembolism and heart failure, but also decreases the survival of patients with impaired left ventricular function; thus, it is considered an independent factor for cardiovascular death. The goal of antiarrhythmic drug therapy for atrial fibrillation is improvement of daily quality of life and cardiovascular prognosis in maintaining sinus rhythm, while ensuring the safety of antiarrhythmic drugs. Antiarrhythmic drugs are prescribed to prevent recurrence of atrial fibrillation; however, they demonstrate limited efficacy. Recently, catheter ablation has been established as a promising new therapy to prevent recurrence of atrial fibrillation, even though this procedure would be difficult to apply clinically because of its complications and the large number of patients requiring treatment. Since the antiarrhythmic drugs remain the first-line, primary therapy for paroxysmal atrial fibrillation, clinicians should select appropriate antiarrhythmic drugs for treatment of paroxysmal atrial fibrillation based on individual patient characteristics. Read More

National Minority Quality Forum
Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2011 National Minority Quality Forum, Inc. All Rights Reserved.